Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA - Breast Cancer Prevention & Early Detection

McGill University

$100,000.00

Targeting EZH2 in breast cancer: Role of epigenetic modification in modulating breast cancer cell plasticity.

EF 2025-26

Résumé
This proposal investigates the role of Ezh2 as a critical regulator breast cancer cell plasticity that ultimately contributes breast cancer heterogeneity, drug resistance and relapse. However, the identification of key molecular events governing this phenomenon is therefore of great importance to the therapeutic management of breast cancer. We hypothesize that one of the molecular players underlying breast cancer heterogeneity is Ezh2 the key enzymatic component of the epigenetic complex known as PRC2.Our vision is that by understanding the role of Ezh2 in breast cancer progression we will uncover information that could lead to new clinical strategies that would synergize with current breast cancer therapeutic strategies.
Programme
Project Grant - PA - Breast Cancer Prevention & Early Detection
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
553182
Name
Muller William J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics 2
Projecttitle
Targeting EZH2 in breast cancer: Role of epigenetic modification in modulating breast cancer cell plasticity.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA - Breast Cancer Prevention & Early Detection
Keyworddelim
Breast Cancer; Epigenetics; Epithelial Mesencymal Transition; Ezh2; Genetic Engineered Mouse Models; Prc2
Abstract
This proposal investigates the role of Ezh2 as a critical regulator breast cancer cell plasticity that ultimately contributes breast cancer heterogeneity, drug resistance and relapse. However, the identification of key molecular events governing this phenomenon is therefore of great importance to the therapeutic management of breast cancer. We hypothesize that one of the molecular players underlying breast cancer heterogeneity is Ezh2 the key enzymatic component of the epigenetic complex known as PRC2.Our vision is that by understanding the role of Ezh2 in breast cancer progression we will uncover information that could lead to new clinical strategies that would synergize with current breast cancer therapeutic strategies.
Competitiondate
202509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muller, William J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~